ArticleAnnals of surgical oncology2025
Differentiation Between Parotid Adenolymphoma and Malignant Tumor Based on Multimodal Functional MRI of Radiomics and Intratumoral Vascular ITSS Classification.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDifferentiating between parotid adenolymphoma and malignant tumors remains challenging. PURPOSE: This study aims to improve preoperative diagnosis accuracy by evaluating the role of multimodal functional magnetic resonance imaging (MRI) and advanced radiomics analysis.
methodsWe retrospectively analyzed 124 patients with adenolymphoma and malignant parotid tumors, divided into primary (n = 84) and test (n = 40) cohorts. Tumor regions were manually labeled on susceptibility-weighted imaging (SWI), diffusion-weighted imaging (DWI), and contrast-enhanced T1-weighted imaging (CE-T1WI). Seven radiomics models were constructed using logistic regression. We also incorporated intratumoral susceptibility signal (ITSS) grading and performed histogram analysis of apparent diffusion coefficient (ADC) maps.
resultsThe united radiomics model combining SWI, DWI, and CE-T1WI showed the highest diagnostic performance (area under the curve (AUC) = 0.95, accuracy = 0.93, specificity = 0.93) in the primary cohort, outperforming single-sequence and double-sequence models. The test set validated the model's good diagnostic performance (AUC = 0.9). ITSS grading significantly differed between adenolymphomas and malignant tumors (p < 0.001). ADC histogram analysis revealed significant differences in mean, 10th percentile, and kurtosis values between the two groups.
conclusionsThe multisequence radiomics model combining DWI, SWI, and CE-T1WI provides a comprehensive and accurate noninvasive approach for differentiating parotid adenolymphoma from malignant tumors. This method helps avoid the risks associated with invasive procedures, such as tumor cell implantation and metastasis, while guiding personalized surgical decision-making. By offering a novel diagnostic tool, this study enhances the precision of preoperative tumor characterization and supports more effective treatment planning and prognosis assessment for patients with parotid gland tumors.
Indexed as
Identifiers
40358780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.